Respiratory viral diseases: access to RNA interference therapy.
Respiratory viral diseases: access to RNA interference therapy.
复制标题
DOI：
10.1016/j.ddstr.2008.01.001
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Barik, Sailen
中科院分区：
文献类型：
--
作者：
Bitko, Vira;Barik, Sailen
本文综述了近年来RNA干扰治疗病毒性呼吸道疾病的研究进展。将短干扰RNA（siRNA）递送至其预期靶组织仍然是这些化合物的大多数治疗应用的最大问题。适当的制剂和化学修饰以提高稳定性将提高RNAi药物在临床应用中的利用率。Charles克雷格-临床病毒学专家
This review summarizes recent experimental achievements in the area of the development of new RNA interference (RNAi) therapeutics for the treatment of viral respiratory diseases. Delivery of short interfering RNA (siRNA) to their intended target tissue remains the biggest problem for most therapeutic applications of these compounds. Appropriate formulations and chemical modifications for improved stability will boost the probability of utilization of RNAi drugs in the clinical applications. Charles Craig – Clinical Virology Specialist